Hamish McArthur

Dr. McArthur is joining Neurotez as the Manufacturing Chief Officer. Hamish is an Executive with 33 years of Bioprocess R&D, Business Development, and Regulatory experience at Pfizer, responsible for the e-CTD and registration of Drug Substance sections of multiple approved products including Macugen®, Eraxis®, Xiaflex®, Elelyso®, and Dalvance®. Hamish participated and led the development teams covering a wide range of fermentation, monoclonal antibody, and novel technology applications including mutasynthesis, and accelerated enzyme evolution, in ovo vaccines. Approved products include Dectomax®, Revolution®, Draxxin®, and Embrex®.

He has more than 50 publications and patents. Dr. Hamish obtained his Ph.D. in Microbial Biochemistry at St. John’s College, the University of Cambridge, and his B.Sc., Biological Sciences, in Microbiology at the University of Edinburgh.

He is currently a consultant to Fortune 100, NASDAQ, and private equity biotechnology companies on the development, registration and manufacture of biotechnological products.